Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + ifosfamide + vinorelbine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of gemcitabine, ifosfamide, and vinorelbine. This regimen is primarily used for treating refractory or relapsed Hodgkin's lymphoma and advanced non-small cell lung cancer. It works through multiple mechanisms: gemcitabine interferes with DNA synthesis, ifosfamide damages DNA through alkylation, and vinorelbine prevents cell division by inhibiting microtubule formation.
- Other names
- IGEV
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + ifosfamide + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + ifosfamide + vinorelbine.